Opinion: Accounting for hope: using ‘mean survival gain’ to price new cancer drugs
ADOBE
Using mean survival gain instead of median survival gain in pricing decisions for new cancer therapies is a better way to account for their value.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario